title: Prognostic significance of serum p53 antibodies in patients with limited-stage small cell lung cancer.
abstract: p53 tumour suppressor gene alterations are one of the most frequent genetic events in lung cancer. A subset of patients with p53 mutation and cancer exhibited circulating serum anti-p53 self-antibodies (p53-Ab). The prevalence of these antibodies in lung cancer is currently being analysed in a multicentric study. In a group of homogeneous SCLC patients, p53-Ab were detected in 20/97 (20.6%) individuals. In this group of patients, Cox's multivariate analysis identified disease extent (p = 0.022), WHO initial performance status greater than 0 (p = 0.005), and the absence of a complete response after 6 months of treatment (p < 0.0001) as independent prognostic variables, with p53-Ab being of borderline significance (p = 0.051). In the subset of limited-stage SCLC patients, Cox's multivariate analysis found p53-Ab (p = 0.033), WHO initial performance status greater than 0 (p = 0.028), and absence of a complete response (p < 0.001) to be independent prognostic variables. Thus, actuarial analysis showed that patients with limited-stage SCLC and p53-Ab had a median survival time of 10 months, whereas limited-stage SCLC patients without p53-Ab had a 17-month median survival time (p = 0.014).Therefore, serum assay of p53-Ab could help to identify a population of SCLC patients with an especially poor prognosis. This population could represent patients with tumours harboring aggressive p53 mutations.
authors.affiliation: Service de Pneumologie, Hôpital Saint-Louis, Paris, France.
authors.forename: G
authors.initials: G
authors.lastname: Zalcman
authors.forename: J
authors.initials: J
authors.lastname: Trédaniel
authors.forename: B
authors.initials: B
authors.lastname: Schlichtholz
authors.forename: T
authors.initials: T
authors.lastname: Urban
authors.forename: B
authors.initials: B
authors.lastname: Milleron
authors.forename: R
authors.initials: R
authors.lastname: Lubin
authors.forename: V
authors.initials: V
authors.lastname: Meignin
authors.forename: L J
authors.initials: LJ
authors.lastname: Couderc
authors.forename: A
authors.initials: A
authors.lastname: Hirsch
authors.forename: T
authors.initials: T
authors.lastname: Soussi
mesh_terms: D015415:Biomarkers / Q000097:blood; D018288:Carcinoma, Small Cell / Q000097:blood* / Q000401:mortality / Q000473:pathology; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000097:blood* / Q000401:mortality / Q000473:pathology; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D011233:Precipitin Tests; D011379:Prognosis; D016016:Proportional Hazards Models; D011446:Prospective Studies; D016019:Survival Analysis; D016159:Tumor Suppressor Protein p53 / Q000097:blood*
chemical_list: D015415:Biomarkers; D016159:Tumor Suppressor Protein p53